Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETON Eton Pharmaceuticals	$14.43 -0.8%	$16.31	$3.25 ▼ $21.48	$389.93M	1.18	270,988 shs	767,234 shs
IOBT IO Biotech	$1.70	$1.33	$0.66 ▼ $1.90	$112M	0.36	292,941 shs	523,701 shs
ITOS iTeos Therapeutics	$10.31 -0.4%	$9.41	$4.80 ▼ $18.13	$396.13M	1.49	699,697 shs	1.16 million shs
SLDB Solid Biosciences	$5.39 -1.5%	$4.07	$2.41 ▼ $10.37	$424.01M	2.34	1.20 million shs	608,308 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETON Eton Pharmaceuticals	-0.76%	-8.67%	+0.91%	+2.49%	+332.04%
IOBT IO Biotech	0.00%	+17.24%	+25.93%	+91.01%	+23.19%
ITOS iTeos Therapeutics	-0.39%	+1.88%	+1.38%	+65.76%	-37.85%
SLDB Solid Biosciences	-1.46%	+2.86%	+19.51%	+113.89%	-37.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETON Eton Pharmaceuticals	2.0994 of 5 stars	3.5	1.0	2.5	1.7	0.6
IOBT IO Biotech	3.624 of 5 stars	3.7	5.0	2.8	2.5	0.6
ITOS iTeos Therapeutics	3.301 of 5 stars	4.1	2.0	2.3	3.3	0.6
SLDB Solid Biosciences	3.4406 of 5 stars	4.6	1.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	105.59% Upside
IOBT IO Biotech	3.33	Buy	$9.33	449.02% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.86	53.80% Upside
SLDB Solid Biosciences	3.17	Buy	$15.10	180.15% Upside

Current Analyst Ratings Breakdown

Latest IOBT, SLDB, ITOS, and ETON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETON Eton Pharmaceuticals	$48.33M	8.01	N/A	N/A	$0.94 per share	15.35
IOBT IO Biotech	N/A	N/A	N/A	N/A	$0.71 per share	N/A
ITOS iTeos Therapeutics	$35M	11.27	N/A	N/A	$16.16 per share	0.64
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$3.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETON Eton Pharmaceuticals	-$3.82M	-$0.18	N/A	28.86	N/A	-9.49%	-3.15%	-1.08%	8/4/2025 (Estimated)
IOBT IO Biotech	-$95.49M	-$1.49	N/A	N/A	N/A	N/A	-162.55%	-125.08%	8/12/2025 (Estimated)
ITOS iTeos Therapeutics	-$134.41M	-$3.04	N/A	N/A	N/A	N/A	-21.37%	-18.55%	8/6/2025 (Estimated)
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)

Latest IOBT, SLDB, ITOS, and ETON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	IOBT IO Biotech	-$0.35	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETON Eton Pharmaceuticals	1.23	1.97	1.43
IOBT IO Biotech	N/A	2.32	2.32
ITOS iTeos Therapeutics	N/A	14.13	14.13
SLDB Solid Biosciences	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETON Eton Pharmaceuticals	27.86%
IOBT IO Biotech	54.76%
ITOS iTeos Therapeutics	97.16%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
ETON Eton Pharmaceuticals	14.89%
IOBT IO Biotech	2.30%
ITOS iTeos Therapeutics	12.50%
SLDB Solid Biosciences	13.63%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.83 million	Optionable
IOBT IO Biotech	30	65.88 million	64.37 million	Not Optionable
ITOS iTeos Therapeutics	90	38.27 million	33.49 million	Optionable
SLDB Solid Biosciences	100	77.52 million	66.95 million	Optionable

IOBT, SLDB, ITOS, and ETON Headlines

Recent News About These Companies

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Buy" from Analysts

4 hours ago | marketbeat.com

SLDB - Solid Biosciences Inc Executives - Morningstar

July 15 at 6:18 PM | morningstar.comM

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

July 10, 2025 | prnewswire.com

SLDB Solid Biosciences Inc. - Seeking Alpha

July 10, 2025 | seekingalpha.com

Solid Biosciences receives FDA approval for CPVT gene therapy IND

July 10, 2025 | investing.com

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular ... - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT

July 10, 2025 | msn.com

Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes

July 9, 2025 | msn.com

SLDB - Solid Biosciences Inc Price vs Fair Value - Morningstar

July 8, 2025 | morningstar.comM

Solid Biosciences Inc. (SLDB) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

SLDB - Solid Biosciences Inc Valuation - Morningstar

June 27, 2025 | morningstar.comM

Solid Biosciences (NASDAQ:SLDB) Raised to "Strong-Buy" at Citigroup

June 27, 2025 | marketbeat.com

Solid Biosciences Inc. (SLDB) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Citigroup Initiates Coverage of Solid Biosciences (SLDB) with Buy Recommendation

June 26, 2025 | msn.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by Brokerages

June 21, 2025 | marketbeat.com

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

...

June 18, 2025 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Receives Buy Rating from HC Wainwright

June 17, 2025 | marketbeat.com

Solid Biosciences Approves Equity Plan Amendment at Meeting

June 13, 2025 | tipranks.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough

May 28, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
By Leo Miller | June 18, 2025
View Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

IOBT, SLDB, ITOS, and ETON Company Descriptions

Eton Pharmaceuticals NASDAQ:ETON

$14.43 -0.11 (-0.76%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$13.70 -0.73 (-5.09%)

As of 07/15/2025 07:30 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

IO Biotech NASDAQ:IOBT

$1.70 0.00 (0.00%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$1.69 -0.01 (-0.59%)

As of 07/15/2025 07:57 PM Eastern

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

iTeos Therapeutics NASDAQ:ITOS

$10.31 -0.04 (-0.39%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$10.30 -0.01 (-0.05%)

As of 07/15/2025 04:24 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Solid Biosciences NASDAQ:SLDB

$5.39 -0.08 (-1.46%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$5.44 +0.06 (+1.02%)

As of 07/15/2025 07:57 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time